Lupin Completes VISUfarma Acquisition, Expands European Ophthalmology Portfolio Across Key Markets

Mumbai: Lupin is sharpening its global specialty play with a completed European acquisition.

Lupin Limited has finalised its acquisition of VISUfarma B.V. from GHO Capital Partners LLP. The move marks a key milestone in the company’s strategy to expand its specialty care portfolio and deepen its presence in Europe. The acquisition brings in a well-established ophthalmology-focused business with strong regional roots.

With this acquisition, Lupin’s ophthalmology portfolio now includes over 60 branded products. These span multiple segments such as dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. The broader portfolio enhances Lupin’s ability to cater to diverse patient needs in the eye care segment.

VISUfarma has an established commercial footprint across Italy, the UK, Spain, Germany, and France. The company also brings a team with deep expertise in ophthalmology and strong relationships in local markets. This integration gives Lupin immediate scale and strengthens its market access across Europe.

Management indicated that the acquisition supports Lupin’s long-term strategy to build a robust specialty franchise. The growing demand for ophthalmology treatments, driven by ageing populations and rising diabetes-related complications, presents a strong opportunity. VISUfarma’s 53 million euro revenue in 2025 further adds to Lupin’s growth momentum. The VISUfarma acquisition positions Lupin to scale its specialty business globally, combining product depth with stronger regional reach in Europe.

Disclaimer: This article is based solely on the company’s stock exchange filing and accompanying press release and does not include external sources or independent verification.